Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is an American biotechnology and biopharmaceutical corporation that specializes in the discovery, development, and commercialization of targeted small-molecule therapies for severe, life-threatening diseases. The company concentrates its commercial activities on specialized rare disease therapeutic areas, with portfolio lines comprising cystic fibrosis transmembrane conductance regulator modulators, cell therapies, and non-opioid pain medications. Its principal revenue drivers consist of global product sales of proprietary prescription medicines, including Trikafta, Kaftrio, Kalydeco, Symdeko, and Orkambi, complemented by emerging gene-editing treatments. Operating as a dominant global biotechnology enterprise, the company maintains a commanding market position in disease-modifying cystic fibrosis treatments worldwide across clinical markets. The enterprise reinvests significant revenue into research and development programs focused on sickle cell disease, beta-thalassemia, acute pain management, and kidney disorders across international markets. The corporation maintains its central executive headquarters in Boston, Massachusetts, United States, and its common stock is listed and traded on the Nasdaq Global Select Market under the ticker symbol VRTX.
64 of the funds FundTelligence covers report a position in Vertex Pharmaceuticals.
- Legal name
- Vertex Pharmaceuticals Inc.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 64
- Exposure themes
- Gene Editing, Genetic Medicine, Precision Medicine & Genomics
Funds holding Vertex Pharmaceuticals
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 7.88 % (full portfolio disclosed, October 2026)
- UBS Biotech Equity Fund — UBS · 7.5 % (largest positions only, September 2026)
- GS Global Future Health Care Equity Portfolio — Goldman Sachs · 4.06 % (largest positions only, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 3.99 % (full portfolio disclosed, September 2026)
- HealthInvest Sustainable Healthcare — HealthInvest · 3.8 % (partially disclosed portfolio, September 2026)
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 3.73 % (largest positions only, September 2026)
- AB International Health Care Portfolio — AllianceBernstein · 3.71 % (largest positions only, September 2026)
- Swedbank Robur Healthcare — Swedbank · 3.53 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 64 funds holding it.